Skip to main content

Table 6 Short-term results of phase II and of retrospective available studies

From: Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study

Author
( a Study)
N. of patients Stage Radiotherapy Compliance RT-CT pCR Tox ≥ 3 Post-op morbidity
De Ridder et al. [24]
(Phase II)
24/13 T3-T4
MRF+
46Gy/23fr/2
SIB 55.2Gy/23fr/2.4Gyfr
100% -noCT 14% 4.2% 8%
Li et al. [25]
(Phase II)
63 T3-T4
N+
41.8Gy/22fr/1.9
SIB 50.6Gy/22fr/2.3Gyfr
100% –100% 31% 14% 7%
Hernando et al. [26]
(Retrospective)
74 T2-T4
N+
45Gy/25fr/1.8
SIB 57.5Gy/25fr/2.3Gyfr
99% – 99% 31% 17.6% 7%
Zhu et al. [27]
(Phase II)
78 T3-T4
N0/N+
50Gy/25fr/2
SIB 55Gy/25fr/2.2Gyfr
100% – 62% 24% 14% 17%
Wang et al. [28]
(Retrospective)
260 T3-T4-
N0/N+
41.8Gy/22fr/1.9
SIB 50.6Gy/22fr/2.3Gyfr
99% – 99% 18.5% 6% 23%
bArbea et al. [29]
(Phase II)
100 T3-T4
N+
47.5Gy/19fr/2.5 and
47.5Gy/20fr/2.4Gyfr
97% – 80% 13% 25% 7%
Our experience 76 T3-T4
N0/N+
45 Gy/25fr/1.8
SIB 52.5–57.Gy/25fr 2.1–2.3Gyfr
97.4% – 84% 22% 10.5% 18%
  1. aAll Studies included concurrent Capecitabine bConcurrent Capecitabine-Oxaliplatin